The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2026 | TP53-mutated AML: clinical outcomes with azacitidine-based therapy
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, comments on the treatment of TP53-mutated acute myeloid leukemia (AML), noting that while the combination of azacitidine and venetoclax shows an increased response rate compared to azacitidine alone, it does not improve overall survival in these patients. This interview took place at the 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, as you know, azacitidine plus venetoclax is the standard of care for acute myeloid leukemia, for all acute myeloid leukemia. But for the patient mutated for TP53, we observe an increase of response rate compared to azacitidine alone, 20% versus 40% for azacitidine plus venetoclax. But at the end, there is no improvement in terms of overall survival. The median overall survival stays around five months...
So, as you know, azacitidine plus venetoclax is the standard of care for acute myeloid leukemia, for all acute myeloid leukemia. But for the patient mutated for TP53, we observe an increase of response rate compared to azacitidine alone, 20% versus 40% for azacitidine plus venetoclax. But at the end, there is no improvement in terms of overall survival. The median overall survival stays around five months. So today, we can say to use azacitidine and venetoclax mainly for patients who could undergo to allo-stem cell transplantation, but for the other patients, the discussion is open to use azacitidine alone or azacitidine-venetoclax.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Abbvie, BMS, Novartis, Servier, Gilead, Jazz Pharma
